Perrigo Company plc (NYSE:PRGO) Shares Acquired by NBC Securities Inc.

NBC Securities Inc. grew its stake in Perrigo Company plc (NYSE:PRGO - Free Report) by 111,240.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,134 shares of the company's stock after acquiring an additional 11,124 shares during the quarter. NBC Securities Inc.'s holdings in Perrigo were worth $312,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Barclays PLC grew its stake in Perrigo by 44.8% in the third quarter. Barclays PLC now owns 120,502 shares of the company's stock valued at $3,160,000 after purchasing an additional 37,268 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Perrigo during the 4th quarter worth approximately $149,000. Allspring Global Investments Holdings LLC raised its stake in shares of Perrigo by 5.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,092,398 shares of the company's stock worth $28,402,000 after acquiring an additional 52,696 shares in the last quarter. Rhumbline Advisers grew its holdings in Perrigo by 0.4% in the fourth quarter. Rhumbline Advisers now owns 370,085 shares of the company's stock worth $9,515,000 after purchasing an additional 1,549 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D increased its position in shares of Perrigo by 13.5% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 77,062 shares of the company's stock worth $1,981,000 after purchasing an additional 9,178 shares in the last quarter. 95.91% of the stock is owned by institutional investors.

Perrigo Stock Performance

PRGO stock traded up $1.43 during trading on Tuesday, reaching $27.60. The company had a trading volume of 1,539,566 shares, compared to its average volume of 1,489,896. The company has a market cap of $3.79 billion, a price-to-earnings ratio of -23.59 and a beta of 0.46. Perrigo Company plc has a twelve month low of $23.14 and a twelve month high of $30.93. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56. The firm has a 50-day simple moving average of $25.94 and a 200-day simple moving average of $26.16.

Perrigo (NYSE:PRGO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.56 by $0.04. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a negative net margin of 3.64% and a positive return on equity of 7.38%. The business's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.29 earnings per share. As a group, sell-side analysts expect that Perrigo Company plc will post 2.56 earnings per share for the current year.

Perrigo Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 17th. Stockholders of record on Friday, May 30th will be issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 4.20%. The ex-dividend date of this dividend is Friday, May 30th. Perrigo's dividend payout ratio is presently -88.55%.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Perrigo from a "hold" rating to a "buy" rating in a research report on Saturday, May 24th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, Perrigo currently has an average rating of "Hold" and a consensus price target of $33.00.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.